GW-405833 – (180002-83-9)

GW-405,833 (L-768,242) is a potent and selective partial agonist for the cannabinoid receptor subtype CB2, with a selectivity of around 1200x for CB2 over CB1 receptors. It exhibits anti-inflammatory and anti-hyperalgesic effects at low doses, with analgesic and ataxic effects at higher doses.

GW-405,833 is being investigated for its potential in treating neuropathic pain and allodynia, conditions often inadequately managed by current therapies. The drug has shown promise in preclinical studies, particularly in reducing inflammatory and neuropathic pain through CB2 receptor activation.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/GW-405,833
https://www.medchemexpress.com/gw-405833.html
https://www.medkoo.com/products/10336
https://www.nature.com/articles/s41401-022-01037-8